Fifteen months ago, Altair Nanotechnologies of Reno thought a licensing deal with Spectrum Pharmaceuticals of Irvine, Calif., might be worth $100 million.
At the moment, it's worth little more than a headache.
Alan Gotcher, Altair's president and chief executive officer, told investors last week that his company is back in arbitration with Spectrum after a November deal fell through.
The arbitration agreement reached late last year called for Altair to receive 140,000 shares of Spectrum stock stock worth about $580,000 last week to settle a dispute over testing of an Altair product that targets kidney disease.
In January, Spectrum backed out, and arbitration started anew.
In a filing with the Securities and Exchange Commission in late March, Spectrum said it invested less than $250,000 in researching Altair's product, Renazorb, and said its future interest in the product is uncertain.
The Spectrum deal cast a shadow, too, over the first-quarter earnings that Altair reported last week.
It reported that its revenues fell to $545,000 from the $1 million it recorded a year earlier.
The difference, Altair said, was a $695,000 payment it received from Spectrum in last year's first quarter.
Altair reported a loss of $4.56 million for the quarter compared with a loss of $2.2 million a year ago.
Gotcher said the company's loss widened because it's gearing up new product development.
He projected that earnings will trend upward the rest of this year.
Comments
Use the comment form below to begin a discussion about this content.
Sign in to comment